COMPARE: Everolimus-eluting stent safer, more efficacious than paclitaxel-eluting stent

February 2010
Cardiology Today;Feb2010, Vol. 13 Issue 2, p17
The article discusses research on the efficacy and safety of everolimus-eluting stent versus paclitaxel-eluting stent in the treatment of patients with cardiovascular problems, with a reference to a study by E. Kedhi that was published in an issue of the "Lancet."


Related Articles

  • Efficacy of paclitaxel-eluting stent implantation in hemodialysis patients. Higashitani, Michiaki; Mori, Fumiaki; Yamada, Norihiro; Arashi, Hiroyuki; Kojika, Asako; Hoshi, Hiromi; Minami, Yuichiro; Yamaguchi, Junichi; Yamauchi, Takao; Takagi, Atsushi; Ogawa, Hiroshi; Hagiwara, Nobuhisa // Heart & Vessels;Nov2011, Vol. 26 Issue 6, p582 

    Hemodialysis patients were recognized as a high-risk group for restenosis after percutaneous coronary intervention in the era of the bare-metal stent. Recently, sirolimus-eluting stents (SES) have reduced restenosis and target lesion revascularization (TLR); however, it has been reported that...

  • Paclitaxel-Eluting Coronary Stents. Ajani, Andrew E.; Waksman, Ron // New England Journal of Medicine;5/13/2004, Vol. 350 Issue 20, p2099 

    A letter to the editor is presented in response to the article "A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease," by G.W. Stone et al. which appeared in the January 15, 2004 issue.

  • Paclitaxel-Eluting Coronary Stents. Stone, Gregg W.; Ellis, Stephen G.; Russell, Mary E. // New England Journal of Medicine;5/13/2004, Vol. 350 Issue 20, p2099 

    A response by G.W. Stone et al to a letter to the editor about their article "A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease," in the January 15, 2004 issue is presented.

  • Long-term follow-up in patients with malignant biliary obstruction after percutaneous placement of uncovered wallstent endoprostheses. Kaskarelis, I.S.; Papadaki, M.G.; Papageorgiou, G.N.; Limniati, M.D.; Malliaraki, N.E.; Piperopoulos, P.N. // Acta Radiologica;Sep1999, Vol. 40 Issue 5, p528 

    Purpose: Evaluation of the treatment of malignant obstructive jaundice by percutaneous insertion of uncovered stents. Material and Methods: 51 patients (35 men, 16 women) with inoperable malignant biliary obstruction underwent percutaneous placement of uncovered...

  • Sirolimus-Eluting Stents Superior to Paclitaxel-Eluting Stents in Diabetics. Boyle, Andrew J. // Clinical Cardiology Alert;Oct2008, Vol. 27 Issue 10, p87 

    The article discusses a research which compared the efficiency of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with diabetic mellitus. Angiographic findings were better in the sirolimus-eluting stents than in the paclitaxel-eluting stent group. In both groups of...

  • The cancer treatment of tomorrow. Marandino, Cristin // Country Journal;Sep/Oct95, Vol. 22 Issue 5, p12 

    Discusses the effectiveness of taxol, a potent drug derived from the bark of Pacific yew trees, in breast and ovarian cancer treatment. Cost per dose; `Science' magazine's projection on the approximate number of yew trees required to use the drug for a wider range of patients; Florida State...

  • Medicinal plants--an update.  // American Nurseryman;8/1/95, Vol. 182 Issue 3, p23 

    Reports on the findings of a study on the effectiveness of the anti-cancer drug, taxol which is derived from the Pacific yew tree. Presentation of the study's results to the American Society of Clinical Oncology; National Cancer Institute's reversion of its recommendations for treating ovarian...

  • Taxol loses its luster as cancer-fighting drug.  // American Nurseryman;4/15/94, Vol. 179 Issue 8, p24 

    Reports on the declining interest in the drug taxol as an anti-cancer drug. Revision of the belief that taxol can be an important additional to the arsenal of anti-cancer drugs; Tests which led to the decline of the drug's reputation as an effective oncological drug.

  • RAS Can Be Safely Managed with Stent-Supported Angioplasty.  // Kidney;Mar/Apr99, Vol. 8 Issue 2, p63 

    Evaluats the success of Plmaz-Schatz stent revascularization of stenotic renal arteries, as well as its impact on renal function, blood pressure control and survival. Creatinine levels after revascularization; Three-year cumulative survival for all patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics